Index -
P/E -
EPS (ttm) -0.02
Insider Own 1.77%
Shs Outstand 67.31M
Perf Week -2.68%
Market Cap 147.63M
Forward P/E -
EPS next Y -0.44
Insider Trans -5.93%
Shs Float 66.52M
Perf Month -14.17%
Income -0.57M
PEG -
EPS next Q -0.08
Inst Own 48.31%
Short Float 5.31%
Perf Quarter 40.65%
Sales 101.21M
P/S 1.46
EPS this Y -3066.67%
Inst Trans -20.06%
Short Ratio 3.98
Perf Half Y 71.65%
Book/sh -0.70
P/B -
EPS next Y -37.53%
ROA -0.24%
Short Interest 3.53M
Perf Year 43.42%
Cash/sh 2.58
P/C 0.85
EPS next 5Y -0.90%
ROE -4417.92%
52W Range 1.04 - 2.86
Perf YTD 40.65%
Dividend Est. -
P/FCF -
EPS past 5Y 67.21%
ROI -
52W High -23.64%
Beta 1.00
Dividend TTM -
Quick Ratio 1.17
Sales past 5Y 28.25%
Gross Margin 95.12%
52W Low 109.62%
ATR (14) 0.18
Dividend Ex-Date -
Current Ratio 1.17
EPS Y/Y TTM 98.62%
Oper. Margin 1.47%
RSI (14) 53.15
Volatility 5.73% 8.48%
Employees 122
Debt/Eq -
Sales Y/Y TTM 39.92%
Profit Margin -0.56%
Recom 2.83
Target Price 2.85
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 109.36%
Payout -
Rel Volume 3.21
Prev Close 2.19
Sales Surprise 35.79%
EPS Surprise 141.41%
Sales Q/Q 32.22%
Earnings Mar 11 AMC
Avg Volume 887.92K
Price 2.18
SMA20 -6.18%
SMA50 15.85%
SMA200 38.86%
Trades
Volume 2,853,490
Change -0.46%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-14-22 Downgrade
BMO Capital Markets
Outperform → Market Perform
$3 → $2.60
Jul-07-22 Downgrade
Wedbush
Outperform → Neutral
$6 → $2
Jul-07-22 Downgrade
Piper Sandler
Overweight → Neutral
$10 → $1.50
Jul-07-22 Downgrade
Mizuho
Buy → Neutral
$16 → $4
Jul-07-22 Downgrade
Jefferies
Buy → Hold
$12 → $2
Jun-24-22 Initiated
BMO Capital Markets
Outperform
$9
Jan-18-22 Upgrade
Barclays
Underweight → Overweight
$7
Nov-15-21 Initiated
BTIG Research
Buy
$16
May-28-21 Downgrade
Barclays
Equal Weight → Underweight
$9 → $7
Mar-29-21 Initiated
JP Morgan
Overweight
$14
Mar-23-21 Upgrade
Jefferies
Hold → Buy
Sep-22-20 Downgrade
Guggenheim
Buy → Neutral
Jun-01-20 Downgrade
Jefferies
Buy → Hold
$16 → $10
May-14-20 Reiterated
H.C. Wainwright
Buy
$16 → $12
Mar-24-20 Upgrade
Wedbush
Neutral → Outperform
Mar-04-20 Initiated
Barclays
Equal Weight
$7
Nov-20-19 Initiated
Guggenheim
Buy
Nov-11-19 Downgrade
Wedbush
Outperform → Neutral
$25 → $8
Jun-13-19 Initiated
Mizuho
Buy
May-14-19 Initiated
Cantor Fitzgerald
Overweight
$21
Show Previous Ratings
Mar-21-24 08:00AM
Mar-18-24 08:00AM
Mar-12-24 09:12AM
08:30AM
06:46AM
(Thomson Reuters StreetEvents)
05:34PM
Loading…
Mar-11-24 05:34PM
05:20PM
04:10PM
Mar-04-24 08:00AM
Feb-27-24 11:52AM
08:00AM
Jan-24-24 08:00AM
Jan-12-24 08:00AM
Jan-04-24 08:00AM
Dec-21-23 08:00AM
12:00PM
Loading…
Nov-13-23 12:00PM
Nov-08-23 10:15AM
Nov-07-23 05:05PM
(Associated Press Finance)
04:15PM
Nov-01-23 08:00AM
Oct-31-23 08:00AM
Oct-30-23 08:00AM
Oct-18-23 04:30PM
Sep-05-23 04:05PM
Aug-25-23 09:35AM
Aug-10-23 04:05PM
Aug-08-23 05:30PM
04:26PM
(Associated Press Finance)
04:15PM
Aug-01-23 08:00AM
09:00AM
Loading…
Jul-20-23 09:00AM
Jul-17-23 08:00AM
Jun-30-23 08:00AM
Jun-08-23 09:02AM
Jun-01-23 04:05PM
May-11-23 06:05AM
May-10-23 08:13AM
(Thomson Reuters StreetEvents) +5.81%
May-09-23 05:35PM
04:26PM
04:15PM
May-05-23 06:34AM
May-01-23 04:01PM
10:01AM
Apr-27-23 10:03AM
Apr-25-23 04:05PM
Mar-30-23 11:26AM
Mar-29-23 06:06AM
Mar-28-23 01:35PM
Mar-27-23 05:35PM
04:15PM
Mar-22-23 07:23PM
Mar-20-23 06:14AM
Feb-28-23 04:05PM
Feb-07-23 06:07AM
Jan-26-23 07:00AM
Jan-17-23 04:05PM
Jan-12-23 05:30AM
Jan-06-23 06:44PM
01:46PM
10:30AM
Jan-05-23 05:11PM
04:19PM
04:05PM
04:05PM
Dec-22-22 05:00PM
07:54AM
Dec-20-22 05:00PM
Dec-07-22 04:30PM
Nov-23-22 12:18PM
Nov-18-22 01:18PM
Nov-17-22 11:14AM
11:09AM
(American City Business Journals)
07:00AM
07:00AM
Nov-08-22 05:35PM
04:10PM
Nov-07-22 04:15PM
Nov-02-22 04:15PM
Nov-01-22 08:00AM
Oct-27-22 05:15PM
Sep-13-22 08:42AM
Sep-12-22 08:00AM
Sep-07-22 06:05PM
Sep-01-22 10:17AM
Aug-05-22 08:30AM
Aug-04-22 05:45PM
04:15PM
Aug-03-22 08:00AM
Aug-01-22 10:01AM
Jul-28-22 10:02AM
08:00AM
Jul-15-22 10:50AM
(American City Business Journals) +7.14%
07:54AM
Jul-14-22 06:05AM
Jul-13-22 04:05PM
Jul-07-22 06:15AM
Jul-06-22 04:05PM
Jun-27-22 08:33AM
Jun-16-22 08:00AM
Jun-01-22 08:00AM
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
McCarthy Sean A. CEO Mar 26 '24 Option Exercise 1.57 109,768 172,874 634,249 Mar 28 07:12 PM McCarthy Sean A. CEO Mar 19 '24 Sale 2.09 20,223 42,175 524,481 Mar 21 04:40 PM BELVIN MARCIA SVP, Chief Scientific Officer Mar 19 '24 Sale 2.09 12,795 26,684 168,579 Mar 21 04:37 PM Landau Jeffrey B Chief Business Officer Mar 19 '24 Sale 2.09 6,562 13,685 110,060 Mar 21 04:36 PM ROWLAND LLOYD A General Counsel Mar 19 '24 Sale 2.09 5,268 10,986 117,728 Mar 21 04:41 PM Ogden Christopher SVP, Finance and Accounting Mar 19 '24 Sale 2.09 2,971 6,196 85,686 Mar 21 04:38 PM McCarthy Sean A. CEO Dec 20 '23 Sale 1.38 13,551 18,710 454,704 Dec 22 04:16 PM ROWLAND LLOYD A General Counsel Dec 20 '23 Sale 1.38 4,077 5,629 97,996 Dec 22 04:11 PM BELVIN MARCIA SVP, Chief Scientific Officer Dec 20 '23 Sale 1.38 4,077 5,628 155,124 Dec 22 04:14 PM Landau Jeffrey B Chief Business Officer Dec 20 '23 Sale 1.38 4,077 5,628 86,622 Dec 22 04:12 PM Ogden Christopher SVP, Finance and Accounting Dec 20 '23 Sale 1.38 1,990 2,747 48,657 Dec 22 04:10 PM Ogden Christopher SVP, Finance and Accounting Dec 17 '23 Option Exercise 0.00 6,875 0 50,647 Dec 19 07:58 PM McCarthy Sean A. CEO Dec 17 '23 Option Exercise 0.00 37,500 0 468,255 Dec 19 07:57 PM Landau Jeffrey B Chief Business Officer Dec 17 '23 Option Exercise 0.00 11,250 0 90,699 Dec 19 07:56 PM ROWLAND LLOYD A General Counsel Dec 17 '23 Option Exercise 0.00 11,250 0 102,073 Dec 19 07:55 PM BELVIN MARCIA SVP, Chief Scientific Officer Dec 17 '23 Option Exercise 0.00 11,250 0 159,201 Dec 19 07:54 PM McCarthy Sean A. CEO Sep 22 '23 Sale 1.30 14,601 18,987 430,755 Sep 22 07:13 PM ROWLAND LLOYD A General Counsel Sep 22 '23 Sale 1.30 5,486 7,135 80,609 Sep 22 07:12 PM BELVIN MARCIA SVP, Chief Scientific Officer Sep 22 '23 Sale 1.30 4,119 5,356 147,951 Sep 22 07:16 PM Landau Jeffrey B Chief Business Officer Sep 22 '23 Sale 1.30 4,119 5,356 76,379 Sep 22 07:15 PM McCarthy Sean A. CEO May 19 '23 Option Exercise 1.57 16,535 26,041 405,356 May 23 04:52 PM Jones Elaine V Director Mar 29 '23 Buy 1.55 5,000 7,750 5,142 Mar 31 07:56 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite